Finance

GSK Clinches $3 Billion Takeover of Human Genome Sciences

July 16, 2012

Price represents a premium of 99% to the HGS closing share price on April 18, 2012, which was the last day of trading before the informal bid was disclosed.

Agence France-Presse

After increasing its bid to $3.0 billion British drugmaker GlaxoSmithKline (IW1000/88) on Monday clinched a takeover of US research partner Human Genome Sciences Inc.

GSK said that it has won the approval of HGS management after lifting its bid to $14.25 per share in cash, from the previous level of from $13 per share.

"The transaction values HGS at approximately US$3.6 billion on an equity basis, or approximately US$3.0 billion net of cash and debt."

GSK had launched a $2.6-billion hostile bid in May after HGS rejected an informal approach the previous month.

Monday's agreed bid represents a premium of 99% to the HGS closing share price on April 18, 2012, which was the last day of trading before the informal bid was disclosed.

Copyright Agence France-Presse, 2012

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.